Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
Start with the original source
This source record has not yet received an editorial summary. Open the publication to read its methods, findings and limitations in context.
Questions for the community
- Which parts of the study design matter most when interpreting this source?
- What would you need to know before applying the findings to a different population?
The community requires an account and moderator review. Nothing is posted automatically.
Study-design labels are drawn from source metadata or provisional title signals and require verification against the methods. These records are educational references, not treatment recommendations.